Repligen purchases 908 Devices’ bioprocessng analytics portfolio for $70M

Repligen (RGEN), and 908 Devices (MASS) announced that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen’s differentiated PAT portfolio that provides its biopharmaceutical and CDMO customers with actionable insights to optimize development processes and improve manufacturing efficiencies. Products acquired from 908 Devices include MAVERICK and MAVEN for real-time monitoring and control of critical bioprocess parameters; REBEL, an at-line cell culture media analyzer; and ZipChip, a high-resolution sample separations device used in the characterization of product quality attributes. The purchase consideration is a payment of $70M in cash. Centerview Partners is acting as financial advisor and Goodwin Procter is serving as legal counsel to Repligen Corporation. Perella Weinberg Partners is acting as financial advisor and Paul Hastings is serving as legal counsel to 908 Devices.